儿童A群C群脑膜炎球菌多糖结合疫苗基础免疫后A群C群脑膜炎球菌多糖疫苗加强免疫的免疫原性和持久性  

Immunogenicity and persistence of immunity following a booster of group A and group C meningococcal polysaccharide vaccine among children who had received primary vaccination with group A and group C meningococcal polysaccharide conjugate vaccine

作　　者：唐继海[1] 李艺星[2] 徐丽[3] 陈霞[1] 毛雷婧 施文 吴丹[2] 邵祝军[3] 尹遵栋[2] 李军宏[2] Tang Jihai;Li Yixing;Xu Li;Chen Xia;Mao Leijing;Shi Wen;Wu Dan;Shao Zhujun;Yin Zundong;Li Junhong(Anhui Provincial Center for Disease Control and Prevention,Hefei 230601,Anhui,China;National Immunization Program,Chinese Center for Disease Control and Prevention,Beijing 100050,China;State Key Laboratory for Infectious Disease Prevention and Control,Institute for Communicable Disease Prevention and Control,Chinese Center for Disease Control and Prevention,Beijing 102206,China;Yingkou Municipal Center for Disease Control and Prevention,Yingkou 115000,Liaoning,China)

机构地区：[1]安徽省疾病预防控制中心,安徽合肥230601 [2]中国疾病预防控制中心免疫规划中心,北京100050 [3]中国疾病预防控制中心传染病预防控制所,传染病预防控制国家重点实验室,北京102206 [4]辽宁省营口市疾病预防控制中心,辽宁营口115000

出　　处：《中国疫苗和免疫》2020年第3期245-248,共4页Chinese Journal of Vaccines and Immunization

摘　　要：目的观察儿童A群C群脑膜炎球菌多糖结合疫苗(Group A and group C meningococcal polysaccharide conjugate vaccine,MPCV-AC)基础免疫后A群C群脑膜炎球菌多糖疫苗(Group A and group C meningococcal polysaccharide vaccine,MPV-AC)加强免疫的免疫原性和持久性。方法在安徽省部分乡镇选择已完成2剂次MPCV-AC基础免疫的3岁儿童进行1剂次MPV-AC加强免疫,采集免疫前和免疫后1个月血标本;选择已完成2剂次MPCV-AC基础免疫和1剂次MPV-AC加强免疫的6岁儿童在第2剂MPV-AC加强免疫前采集血标本;检测所有儿童的A群和C群脑膜炎奈瑟菌血清功能性杀菌抗体,分析抗体阳性率、阳转率和几何平均滴度(Geometric mean titer,GMT)。结果在69名3岁儿童中,MPV-AC免疫前A、C群抗体阳性率分别为73.91%、47.83%;免疫后阳性率均为100%,阳转率分别为75.36%、94.20%,GMT分别为1:1109.69、1:2632.68。在75名6岁儿童中,A、C群抗体阳性率分别为94.67%、64.00%(与3岁儿童免疫后相比,Fisher精确概率法,P=0.121;x2=30.57,P=0.000),GMT分别为1:149.78、1:42.22(与3岁儿童免疫后相比,U=866.00,P=0.000;U=570.00,P=0.000)。结论完成MPCV-AC基础免疫的3岁儿童进行1剂次MPV-AC加强免疫的免疫原性良好但免疫持久性不足3年,建议增加第2剂次加强免疫。Objective To assess immunogenicity and persistence of immunity following a booster dose of group A and group C meningococcal polysaccharide vaccine(MPV-AC)among children who had received primary vaccination with group A and group C meningococcal polysaccharide conjugate vaccine(MPCV-AC).Methods We enrolled 3-year-old children in Anhui province who had received 2 primary doses of MPCV-AC.We obtained blood samples before and 1 month after administering a booster dose of MPV-AC.We also enrolled 6-year-old children who had received 2 primary doses of MPCV-AC and 1 booster dose of MPV-AC and obtained blood samples before giving a second booster dose of MPV-AC.We tested all blood samples for functional bactericidal antibodies against serogroup A and serogroup C Neisseria meningitidis to determine positivity,seroconversion and geometric mean titer(GMT)of antibodies.Results Among 693-year-old children,positivity rates of antibodies against serogroup A and serogroup C were 73.91%and 47.83%before a booster dose of MPV-AC;after booster vaccination,positivity rates were all 100%,and seroconversion rates were 75.36%and 94.20%,with GMTs of 1:1109.69 and 1:2632.68.Among 756-year-old children,positivity rates of antibodies against serogroup A and serogroup C were 94.67%and 64.00%,respectively(compared with postbooster positivity in 3-year-olds:Fisher’s exact test,P=0.121;x^2=30.57,P=0.000),with GMTs of 1:149.78 and 1:42.22(compared with post-booster GMTs in 3-year-olds:U=866.00,P=0.000;U=570.00,P=0.000).Conclusions A booster dose of MPVAC had a good immunogenicity profile among 3-year-old children who had finished primary vaccination with MPCVAC,but immunity persisted less than 3 years.We suggest a second MPV-AC booster dose.

关 键 词：流行性脑脊髓膜炎 A群C群脑膜炎球菌多糖疫苗 A群C群脑膜炎球菌多糖结合疫苗 免疫原性 免疫持久性 

分 类 号：R515.2[医药卫生—内科学] R186.9[医药卫生—临床医学]